OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico

April 26th, 2017|0 Comments

Companies Negotiating Joint Venture for Clinical Development of ProscaVax for Prostate Cancer in Europe BATON ROUGE, LA--(April 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or [...]

OncBioMune Licenses Tretinoin for the Treatment of Acute Promyelocytic Leukemia Throughout Mexico, Central and Latin America

April 20th, 2017|0 Comments

BATON ROUGE, LA--(April 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Prepares Submission Seeking Marketing Approval for Anti-D Immunoglobulin in Mexico

April 18th, 2017|0 Comments

BATON ROUGE, LA--(April 18, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products [...]

OncBioMune and Gem Pharmaceuticals Finalizing Partnership Terms to Develop New Cancer Drug for Mexico, Central and Latin America Markets

March 30th, 2017|0 Comments

BATON ROUGE, LA--(March 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products [...]

OncBioMune Sales of Bekunis® and Cirkused® Exceed Forecast by 164 Percent in First Six Months on Market

March 27th, 2017|0 Comments

BATON ROUGE, LA--(March 27, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico

March 20th, 2017|0 Comments

BATON ROUGE, LA--(March 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib

March 14th, 2017|0 Comments

BATON ROUGE, LA--(March 14, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network

March 13th, 2017|0 Comments

BATON ROUGE, LA--(March 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting

February 2nd, 2017|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, [...]

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

January 26th, 2017|0 Comments

BATON ROUGE, LA--(January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

Departments of Urology and Oncology Approve Protocol for OncBioMune’s Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

January 18th, 2017|0 Comments

OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is [...]

OncBioMune Submitting Clinical Trial of World’s First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute

January 10th, 2017|0 Comments

BATON ROUGE, LA--(January 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer

December 28th, 2016|0 Comments

BATON ROUGE, LA--(December 28, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology

December 12th, 2016|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, [...]

OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer

December 8th, 2016|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to [...]

OncBioMune Provides Update on Acquisition of Vitel Laboratorios

December 7th, 2016|0 Comments

BATON ROUGE, LA--(December 07, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a [...]

OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition

November 11th, 2016|0 Comments

BATON ROUGE, LA--(November 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Signs Term Sheet to Acquire Vitel Laboratorios, S.A. de C.V.

November 3rd, 2016|0 Comments

BATON ROUGE, LA--(November 03, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a [...]

Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board

October 24th, 2016|0 Comments

BATON ROUGE, LA--(October 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico

October 19th, 2016|0 Comments

BATON ROUGE, LA--(October 19, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]